| First-in-human study of mivebresib (ABBV-075), an oral pan-inhibitor of bromodomain and extra terminal proteins, in patients with relapsed/refractory solid tumors SA Piha-Paul, JC Sachdev, M Barve, P LoRusso, R Szmulewitz, SP Patel, ... Clinical Cancer Research 25 (21), 6309-6319, 2019 | 132 | 2019 |
| PTEN loss in the fallopian tube induces hyperplasia and ovarian tumor formation A Russo, AA Czarnecki, M Dean, DA Modi, DD Lantvit, L Hardy, S Baligod, ... Oncogene 37 (15), 1976-1990, 2018 | 78 | 2018 |
| Targeting of follicle stimulating hormone peptide-conjugated dendrimers to ovarian cancer cells DA Modi, S Sunoqrot, J Bugno, DD Lantvit, S Hong, JE Burdette Nanoscale 6 (5), 2812-2820, 2014 | 60 | 2014 |
| Mutant p53 expression in fallopian tube epithelium drives cell migration SM Quartuccio, S Karthikeyan, SL Eddie, DD Lantvit, E Ó hAinmhire, ... International journal of cancer 137 (7), 1528-1538, 2015 | 53 | 2015 |
| A phase 1 study of the pan‐bromodomain and extraterminal inhibitor mivebresib (ABBV‐075) alone or in combination with venetoclax in patients with relapsed/refractory acute … G Borthakur, O Odenike, I Aldoss, DA Rizzieri, T Prebet, C Chen, ... Cancer 127 (16), 2943-2953, 2021 | 47 | 2021 |
| Insulin and insulin-like growth factor signaling increases proliferation and hyperplasia of the ovarian surface epithelium and decreases follicular integrity through … SM King, DA Modi, SL Eddie, JE Burdette Journal of ovarian research 6 (1), 1-15, 2013 | 41 | 2013 |
| PAX2 function, regulation and targeting in fallopian tube-derived high-grade serous ovarian cancer DA Modi, RD Tagare, S Karthikeyan, A Russo, M Dean, DA Davis, ... Oncogene 36 (21), 3015-3024, 2017 | 25 | 2017 |
| Gonadotropins activate oncogenic pathways to enhance proliferation in normal mouse ovarian surface epithelium TS Hilliard, DA Modi, JE Burdette International journal of molecular sciences 14 (3), 4762-4782, 2013 | 23 | 2013 |
| Reduced PAX2 expression in murine fallopian tube cells enhances estrogen receptor signaling JA Colina, P Varughese, S Karthikeyan, A Salvi, DA Modi, JE Burdette Carcinogenesis 41 (5), 646-655, 2020 | 15 | 2020 |
| First-in-Human Study of Abbv-621, a TRAIL Receptor Agonist Fusion Protein, in Patients (Pts) with Relapsed/Refractory (RR) Acute Myeloid Leukemia (AML) and Diffuse Large B-Cell … MJA de Jonge, BA Carneiro, L Devriese, T Doi, S Penugonda, AM Petrich, ... Blood 134, 3924, 2019 | 13 | 2019 |
| Results from the first-in-human study of mivebresib (ABBV-075), a pan-inhibitor of bromodomain and extra terminal proteins, in patients with relapsed/refractory acute myeloid … O Odenike, JE Wolff, G Borthakur, IT Aldoss, D Rizzieri, T Prebet, B Hu, ... Journal of Clinical Oncology 37 (15_suppl), 7030-7030, 2019 | 13 | 2019 |
| Eftozanermin alfa (ABBV-621) monotherapy in patients with previously treated solid tumors: findings of a phase 1, first-in-human study P LoRusso, MJ Ratain, T Doi, DW Rasco, MJA de Jonge, V Moreno, ... Investigational New Drugs 40 (4), 762-772, 2022 | 8 | 2022 |
| Activity of eftozanermin alfa plus venetoclax in preclinical models and patients with acute myeloid leukemia SK Tahir, E Calvo, BA Carneiro, J Yuda, A Shreenivas, ... Blood Journal, blood. 2022017333, 2023 | 7 | 2023 |
| Co-clinical Modeling of the Activity of the BET Inhibitor Mivebresib (ABBV-075) in AML DH Albert, NC Goodwin, AM Davies, J Rowe, G Feuer, M Boyiadzis, ... In Vivo 36 (4), 1615-1627, 2022 | 4 | 2022 |
| Two phase 1b studies evaluating the safety and tolerability of BET inhibitors, ABBV-744 and mivebresib, as monotherapies and in combination with ruxolitinib or navitoclax in … J Mascarenhas, R Saab, D Brackman, DA Modi, L Abraham, JE Ward, ... Blood 136, 18-19, 2020 | 4 | 2020 |
| Ex vivo drug sensitivity and functional genomics platform identifies novel combinations targeting intrinsic and extrinsic apoptotic signaling pathways in multiple myeloma AS Silva, R Renatino-Canevarolo, MB Meads, MDCS Silva, ... Blood 136, 49-50, 2020 | 2 | 2020 |
| First-In-Human Study of a Trail Receptor Agonist Fusion Protein, Eftozanermin Alfa, in Patients with Relapsed/Refractory Acute Myeloid Leukemia and Diffuse Large B-Cell Lymphoma M Jongen-Lavrencic, J Yuda, R Mous, A Olszewski, M Nijland, S Abedin, ... CLINICAL LYMPHOMA MYELOMA & LEUKEMIA 20, S177-S177, 2020 | 2 | 2020 |
| Biomarker modulation by mivebresib (ABBV-075)+/-venetoclax in relapsed/refractory acute myeloid leukemia GM Borthakur, O Odenike, I Aldoss, DA Rizzieri, T Prebet, DA Modi, ... Blood 134, 539, 2019 | 2 | 2019 |
| Gene expression and cytokine modulation in a first in human (FIH) study of a pan BET inhibitor ABBV-075 in solid tumors. BH O'Neil, D Modi, P LoRusso, S Wong, M Motwani, JC Sachdev, JE Wolff, ... Journal of Clinical Oncology 36 (15_suppl), 2570-2570, 2018 | 1 | 2018 |
| Pharmacodynamic effects in blood and tumor tissue of eftozanermin alfa, a tumor necrosis factor-related apoptosis-inducing ligand receptor agonist. M Motwani, D Modi, S Penugonda, C Zhang, J Palma, A Cunningham, ... Journal of Clinical Oncology 38 (15_suppl), e15668-e15668, 2020 | | 2020 |
